| Course | HCA 320 Healthcare Policy and Economics |
|---|---|
| Module | Module 6 |
| Paper type | Discussion post |
| Length | About 438 words |
| Format | Discussion post with APA 7 citations |
| School | Aspen University |
| Program | Health Care Administration |
| Updated | October 2026 |
Free sample paper for HCA 320 Module 6
Module 6 Discussion: Initial Post
Six Billion Dollars and Thirteen Drugs: Weighing the Trade-Off in Medicare Drug Price Negotiation
For decades Medicare was barred from negotiating prices for the drugs its Part D plans cover. The Inflation Reduction Act of 2022 changed that for a limited set of high-spending drugs, and the first results show both what the policy gains and what it may cost. In August 2024, CMS announced negotiated prices for the first ten drugs, including widely used treatments for diabetes, blood clots, and heart failure, taking effect on January 1, 2026. CMS estimated that if those prices had been in effect in 2023, net spending on the ten drugs would have been 22 percent lower, about $6 billion, and that people enrolled in Medicare drug coverage would save about $1.5 billion in out-of-pocket costs in 2026. The negotiated prices ranged from 38 to 79 percent below list prices, and about nine million people with Medicare use at least one of the drugs (Centers for Medicare & Medicaid Services [CMS], 2024).
The economic objection is that lower prices reduce the expected return on developing new drugs, and so reduce innovation. The size of that effect matters. The Congressional Budget Office estimated that the law's drug pricing provisions would lead to about 13 fewer new drugs out of roughly 1,300 over the next 30 years, a reduction of about 1 percent, with most of the effect falling in the later decades (Cubanski et al., 2023). Industry groups argue the effect will be larger, especially for pills and other small-molecule drugs, which the law exposes to negotiation after fewer years on the market than biologics. The trade-off is real, but the two sides are not equally visible: the savings go to identifiable people now, while the forgone drugs are statistical and decades away.
I think this is where economics helps. The U.S. pays more for health care mostly because of higher prices, not more use (Anderson et al., 2003), and drugs are a clear case. A policy that lowers prices for a few older, high-spending drugs while leaving newer drugs untouched for years tries to keep most of the reward for innovation while cutting spending on drugs that have already earned their return. Whether it strikes the right balance depends on how many drugs are selected over time and whether manufacturers respond by raising launch prices, which a manager should watch because it affects hospital and clinic drug budgets too.
Question for classmates: do you think the savings for current patients justify a possible 1 percent reduction in new drugs, and would your answer change if the estimate were 5 or 10 percent?
References
Anderson, G. F., Reinhardt, U. E., Hussey, P. S., & Petrosyan, V. (2003). It's the prices, stupid: Why the United States is so different from other countries. Health Affairs, 22(3), 89-105. https://doi.org/10.1377/hlthaff.22.3.89
Centers for Medicare & Medicaid Services. (2024). Medicare Drug Price Negotiation Program: Negotiated prices for initial price applicability year 2026 [Fact sheet]. https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026
Cubanski, J., Neuman, T., & Freed, M. (2023). Explaining the prescription drug provisions in the Inflation Reduction Act. KFF. https://www.kff.org/medicare/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/
Reading the HCA 320 Module 6 assignment instructions
Aspen's HCA 320 Module 6 discussion typically asks you to analyze the economic trade-offs of a current health policy with data. Choose one policy and describe what it does. Report its measured or estimated benefits with sources. Report its estimated costs, including indirect ones such as effects on innovation. Compare the size and timing of benefits and costs. Use an economic idea to judge the balance. Name what managers should watch. Close with something for peers to answer, and respect the length cap. Use official estimates where they exist, and say when a figure is a projection rather than a result, since many policy debates mix the two.
How the HCA 320 Module 6 example is put together
The post opens with the change: Medicare could not negotiate drug prices until the 2022 law. It reports the ten drugs, the price reductions, the estimated savings and the number of people affected. It presents the innovation objection and the budget office's estimate of about 13 fewer drugs out of 1,300 over 30 years. It notes industry arguments that small-molecule drugs face negotiation sooner. A highlighted sentence observes that savings go to identifiable people now while forgone drugs are statistical and decades away. It uses evidence on prices to argue that the law targets older drugs that have already earned their return. It names launch prices as a risk for hospital and clinic budgets and asks classmates to weigh present savings against future drugs.
HCA 320 Module 6 rubric: what earns full marks
Discussion posts in HCA 320 earn marks for an accurate description of the policy, credible data on both sides of the trade-off, economic reasoning and a clear position. This post earns credit by quantifying the innovation concern instead of dismissing or exaggerating it. The CMS 2024 announcement of negotiated prices supplies the savings, Cubanski, Neuman and Freed's 2023 explainer for KFF reports the budget office estimate and Anderson and colleagues' 2003 article supports the point about prices. The observation about the visibility of benefits and costs shows economic thinking about how policies are judged. Naming launch prices as a risk links the national policy to budgets that health care managers actually control.
Common HCA 320 Module 6 mistakes, and how to avoid them
Drug pricing posts often take a side without numbers. Report savings and innovation estimates. Another common gap is treating projections as results. Label them. Students also ignore timing; savings now and costs decades away are not the same. Use an economic concept, such as price versus quantity. Name what managers should watch, such as launch prices. Keep within the word count. Avoid partisan language. In replies, add evidence from another country's drug pricing, such as how reference pricing works in Germany or Canada. Finally, take a position on the trade-off, since a post that only lists both sides gives classmates little to engage with.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Aspen University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCA 320 and Health Care Administration sample papers
- HCA 320 Module 1: Health Care Market Economics
- HCA 320 Module 2: Reimbursement Models Discussion
- HCA 320 Module 3: Health Policy Process Paper
- HCA 320 Module 4: Medicaid Coverage Gap Analysis
- HCA 320 Module 5: Policy Advocacy Brief
- HCA 320 Module 7: Competitive Analysis and SWOT
- HCA 320 Module 8: Executive Brief and Proposal
- HCA 105 Module 7: Patient Teaching Sheet for an ACE Inhibitor
- HCA 415 Module 4: Justice and Scarce Resources
- HCA 130 Module 3: Plain Language for Patients
- HCA 110 Module 2: Verifying Benefits and Estimating Cost
HCA 320 Module 6 questions, answered
What does the HCA 320 Module 6 discussion usually ask for?
Discussions in this part of HCA 320 often ask you to analyze a current health policy using data, including its economic trade-offs and who is affected. Aspen does not publish module deliverables, so your classroom's instructions govern.
How much will Medicare drug price negotiation save?
CMS estimated that the first ten negotiated prices would have reduced net spending on those drugs by 22 percent, about $6 billion, had they applied in 2023, and would save enrollees about $1.5 billion out of pocket in 2026.
Will negotiation reduce new drug development?
The Congressional Budget Office estimated about 13 fewer new drugs out of roughly 1,300 over 30 years, about 1 percent, though industry groups expect a larger effect.
Where can I find a free HCA 320 Module 6 sample paper?
The full HCA 320 Module 6 post is above, weighing about $6 billion in Medicare drug savings against an estimated 13 fewer new drugs over 30 years.
Will Medicare negotiation reduce new drugs in HCA 320 Module 6?
The Congressional Budget Office estimated about 13 fewer new drugs out of roughly 1,300 over 30 years, about 1 percent, mostly in later decades. Industry argues the effect will be larger.